| Date Filed | Type | Description |
| 10/13/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 10/10/2023 |
SC 13G
| SPHERA FUNDS MANAGEMENT LTD. reports a 5.1% stake in Jasper Therapeutics, Inc. |
| 10/10/2023 |
8-K
| Investor presentation |
| 10/10/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 08/11/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/11/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/11/2023 |
8-K
| Quarterly results |
| 06/08/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/02/2023 |
8-K
| Investor presentation |
| 05/08/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/05/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 04/21/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/21/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/21/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/14/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/14/2023 |
8-K
| Quarterly results |
| 04/13/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/13/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 03/08/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/08/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/08/2023 |
8-K
| Quarterly results |
| 02/27/2023 |
SC 13D
| Velan Capital Investment Management LP reports a 10.2% stake in Jasper Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/06/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 01/31/2023 |
SC 13D/A
| Carlyle Group Inc. reports a 8% stake in Jasper Therapeutics, Inc. |
| 01/30/2023 |
SC 13G
| Soleus Capital Master Fund, L.P. reports a 5.7% stake in JASPER THERAPEUTICS, INC. |
| 01/27/2023 |
SC 13G/A
| Velan Capital Investment Management LP reports a 10.2% stake in Jasper Therapeutics, Inc. |
| 01/27/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Jasper Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares REDWOOD CITY, Calif., January 27, 2023 – Jasper Therapeutics, Inc. , a biotechnology company focused on developing novel antibody therapies targeting c-Kit to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes as well as novel stem cell transplant conditioning regimes, announced today the closing of its previously announced underwritten public offering of 69,000,000 shares of its common stock, at a public offering price of $1.50 per share, which includes the exercise in full by the underwriters of their option to purchase up to 9,000,000 additional shares of common stock. The gross proce..." |
|
| 01/25/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"UNDERWRITING AGREEMENT",
"OPINION OF PAUL HASTINGS LLP",
"Jasper Therapeutics Announces Pricing of $90 Million Public Offering of Common Stock REDWOOD CITY, Calif., January 25, 2023 – Jasper Therapeutics, Inc. , a biotechnology company focused on developing novel antibody therapies targeting c-Kit to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes as well as novel stem cell transplant conditioning regimes, announced today the pricing of its underwritten public offering of 60,000,000 shares of its common stock. Each share of common stock will be sold at a public offering price of $1.50 per share, for gross proceeds of approximately $90 million, before deducting underwriting discounts and commissions and offering expenses. Jasper intends to use the net proceeds from the offering for ge..." |
|
| 01/25/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 01/24/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 01/24/2023 |
8-K
| Investor presentation |
|